Findings from the COMPASS trial, aimed at establishing "the feasibility of a comprehensive real-time genomic analysis of pancreatic ductal adenocarcinoma (PDAC) using whole genome sequencing and RNA sequencing". While phenotypic profiling has been shown to be effective in treatment-based outcomes, a significant challenge is the 1.5-2 months of time required to receive whole genome sequencing results.
Click here to learn more.
Findings from a recent study presented at the ESMO Sarcoma and Rare Cancer Congress indicate a substantial gap between precision oncology and real-world access to high-quality cancer treatments, with "only one in five patients with advanced rare cancers able to access treatment matched through individual molecular profiling." In addition, the study found very limited patient enrollment in clinical trials for rare cancer care; out of 304 patients recommended for clinical trials, only 6 were enrolled."
Click here to learn more.
Program details: Morfouace M, et al.Final analysis of the pan-European Arcagen study for molecular profiling and access to treatment for rare cancers: A joint EORTC-EURACAN initiative. ESMO Sarcoma and Rare Cancers Congress 2026 - Abstract 81MO
The European Society for Medical Oncology (ESMO) recently unveiled a draft report on "preventing work-related psychosocial risks that can lead to burnout in oncologists." Targeted measures mentioned in the report include adequate staffing levels, worker control over workload, flexible scheduling, limits on overtime, and enhanced job security.
Click here to read the draft report.
